read theCongregationLog.

Most AI initiatives in private equity portfolios never translate into EBITDA uplift. This article explains why value gets lost, how ROI fog forms, and what operating partners consistently underestimate.

Private equity has poured billions into MSP roll-ups over the last decade. The thesis is familiar: acquire strong regional operators, standardise operations, unlock scale, and expand margins. On paper, it works. In reality, most MSP platforms hit an invisible wall somewhere between acquisition #2 and #4.

Across private equity portfolios, the same conversation repeats itself. An AI pilot shows promise. A proof of concept is funded. Early results look encouraging. Then time passes.

Let’s be clear: "prospects are drowning in sales spam."

At Panamorphix, every product we build — from transformation tools to immersive dashboards — runs on one core engine: Panalitics.

In healthtech, it’s easy to think success means “building an app.” Investors like apps, patients download them, and developers can produce them quickly. But in reality, **health technology that makes a difference goes far beyond an app icon on a phone.**

While clients explain a challenge, Mark is already designing the architecture, mapping dependencies, stress-testing workflows, and sketching the MVP — all mentally, all in real time. And by the time the meeting ends, he’s already three steps into solution mode.

Behind every great digital system is someone who knows how to make it commercially viable. At Panamorphix, that person is Ashley Bishop — a consultant who sits at the intersection of business development, emerging technology, and strategic execution.

Behind every successful digital transformation, there’s a strategist who can translate complexity into clarity. At Panamorphix, that’s Angela Knox — Co-founder, Chief Marketing Officer, and the steady hand guiding both our internal ventures and client strategies.